Ellence

(Epirubicin)

ApprovedSmall molecule

Epirubicin is a chemotherapy drug used to treat various types of cancer, including breast cancer and other solid tumors, by killing cancer cells and slowing their growth.[2] Ellence is currently approved and in use across 28 indications[4].[1]

Ellence is one of 631 small molecule programs targeting Breast Cancer. It is currently in Approved.

Indications

198

Total Trials

Active Trials

630

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

Breast CancerCompleted

Esophageal AdenocarcinomaApproved

Nasopharyngeal CarcinomaApproved

Germ Cell TumorApproved

Thrombotic DiseaseApproved

Urinary Bladder CancerApproved

Breast NeoplasmApproved

Inflammatory Breast CarcinomaApproved

Non-Hodgkins LymphomaApproved

SepsisApproved

Breast CancerApproved

Completed

Esophageal AdenocarcinomaApproved

Approved

Nasopharyngeal CarcinomaApproved

Approved

Germ Cell TumorApproved

Approved

Thrombotic DiseaseApproved

Approved

Urinary Bladder CancerApproved

Approved

Breast NeoplasmApproved

Approved

Inflammatory Breast CarcinomaApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

SepsisApproved

Approved

Showing 10 of 28 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Ellence

Adenocard

2 3

Voltaren

Novartis

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 5

Duragesic-100

CCephalon

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 7

Tricor

JJagotec

Preclinical

1 8

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 9

Nubain

AAultman Health Foundation

Preclinical

1 10

Rilvegostomig

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Neoadjuvant Therapy

NCT04172259

Q4 2026

Phase 2/3Active, not recruiting

Breast Cancer

NCT04290793

Phase 2Recruiting

Breast Cancer

NCT06389006

Phase 2Active, not recruiting

Lymphoma

NCT04067037

Phase 2Recruiting

Breast Cancer

NCT05447702

Phase 2Not yet recruiting

Breast Cancer

NCT06470633

Clinical

Trials by Indication[1]

Breast Cancer114 trials

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

Recruiting·RRemeGen Co., Ltd.·Phase 2·NCT06389006·79 enrolled

QL1706 Plus Chemotherapy as Neoadjuvant Therapy in Early High-Risk ER+/HER2- Breast Cancer

Not yet recruiting·FFudan University·Phase 2·NCT06404463·76 enrolled

Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer

Terminated· GSK logo

GSK·Phase 2·NCT01220128·66 enrolled

Show 111 more trials

Randomized Phase II Study of Epirubicin vs Caelyx in Pretreated Metastatic Breast Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT00431795·100 enrolled

NeoMET Study in Neoadjuvant Treatment of Breast Cancer

Terminated·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT01929811·92 enrolled

Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer

Recruiting·KKarolinska University Hospital·Phase 2·NCT05900206·370 enrolled

TCb vs EC-T in High Risk ER+/HER2- Breast Cancer

Recruiting·FFudan University·Phase 3·NCT05901428·1,736 enrolled

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Completed·GGBG Forschungs GmbH·Phase 3·NCT02125344·961 enrolled

A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01966471·1,846 enrolled

Six vs 12 Months of Trastuzumab With Docetaxel Following FEC as Adjuvant Treatment in N+ Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00615602·489 enrolled

Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer

Unknown status·ZZhimin Shao·Phase 2·NCT01428414·100 enrolled

Epirubicin and Docetaxel Combination (ET) or Epirubicin Followed by Docetaxel (E/T) for Node Negative (N0) High Risk Breast Cancer Patients

Completed·HHellenic Oncology Research Group·Phase 3·NCT00424606·658 enrolled

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01593020·54 enrolled

Cytoxan, Epirubicin and Capecitabine in Women With Breast Cancer

Completed·—·N/A·NCT00146588·55 enrolled

Sequential Administration of FE75C and Docetaxel Versus Docetaxel/Cyclophosphamide in HER-2 Negative, Node Positive Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT01985724·650 enrolled

Weekly Gemcitabine, Epirubicin, and Docetaxel in Locally Advanced or Inflammatory Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193050·110 enrolled

Adjuvant FEC Versus EP in Breast Cancer (MIG5)

Completed·IIRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy·Phase 3·NCT02450058·1,055 enrolled

Phase II Trial for Large ER-Negative Breast Cancers

Completed·UUniversity of Colorado, Denver·Phase 2·NCT01869192·72 enrolled

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02132949·401 enrolled

Randomized Phase III Trial Comparing Sequential Administration of FE75C Followed by Docetaxel Versus Paclitaxel as Adjuvant Chemotherapy in Axillary Lymph Node (+) Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00431080·478 enrolled

Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients

Completed·PPalleos Healthcare GmbH·Phase 2·NCT03272477·257 enrolled

Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer

Terminated·HHellenic Oncology Research Group·Phase 2·NCT01985841·34 enrolled

Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT03725059·1,240 enrolled

Epirubicin and Vinorelbine in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Terminated·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00176488·31 enrolled

Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer

Suspended·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT02897050·170 enrolled

BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab

Terminated·NNSABP Foundation Inc·Phase 3·NCT00625898·3,509 enrolled

Pyrotinib as Neoadjuvant Agent for Non-objective Response HER2-positive Early Breast Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04717531·60 enrolled

A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer

Not yet recruiting·SShanghai JMT-Bio Inc.·Phase 3·NCT07441460·1,800 enrolled

Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study

Not yet recruiting·CChinese Academy of Medical Sciences·N/A·NCT05287308·500 enrolled

Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00038402·74 enrolled

A Study of Genetic Based Chemotherapy Dosing for Breast Cancer Patients

Unknown status·AAHS Cancer Control Alberta·Phase 2·NCT01740271·48 enrolled

Breast Cancer Treated by Neoadjuvant Chemotherapy

Completed·CCentre Jean Perrin·Phase 2·NCT00425516·264 enrolled

Randomized Phase III Trial With Docetaxel Plus Epirubicine Versus Docetaxel Plus Capecitabine for Metastatic Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 3·NCT00429871·272 enrolled

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT03647280·50 enrolled

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

Completed·NNSABP Foundation Inc·Phase 3·NCT00087178·2,722 enrolled

Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)

Recruiting·WWest China Hospital·Phase 2·NCT05447702·35 enrolled

Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer

Recruiting·UUniversity of Chicago·Phase 2·NCT06291064·85 enrolled

Imaging for Response Assessment of Neoadjuvant Chemotherapy in Primary Breast Cancer (GALADON)

Terminated·WWest German Study Group·Phase 2·NCT01690325·21 enrolled

To Evaluate the Efficacy of Adebrelimab Combined With Chemotherapy After HIFU Induction Neoadjuvant Therapy HR+/HER2- Breast Cancer

Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06470633·29 enrolled

A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients

Completed·PPrestige Biopharma Limited·Phase 3·NCT03013504·503 enrolled

Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

Terminated·WWashington University School of Medicine·Phase 2·NCT01779050·7 enrolled

Neo-adjuvant Gemcitabine, Epirubicin, ABI-007 (GEA) in Locally Advanced or Inflammatory Breast Cancer

Completed·SSCRI Development Innovations, LLC·Phase 2·NCT00193206·123 enrolled

Addition of Vismodegib to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Patients

Unknown status·—·Phase 2·NCT02694224·40 enrolled

Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE)

Active, not recruiting·FFudan University·Phase 3·NCT04296175·808 enrolled

EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer

Recruiting·FFudan University·Phase 3·NCT05883852·1,406 enrolled

Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 3·NCT00336791·273 enrolled

Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer

Active, not recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT04872985·140 enrolled

Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer

Terminated·SSCRI Development Innovations, LLC·Phase 2·NCT00193024·90 enrolled

To Evaluate the Efficacy and Safety of Capecitabine Prior to Surgery in Women With Breast Cancer

Completed· Roche logo

Roche·Phase 2·NCT02846428·182 enrolled

Paclitaxel Followed by FEC Versus Paclitaxel and RAD001 Followed by FEC In Women With Breast Cancer

Unknown status·MM.D. Anderson Cancer Center·Phase 2·NCT00499603·62 enrolled

A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis by Detecting CTCs

Unknown status·—·Phase 2·NCT02510781·200 enrolled

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT01358877·4,804 enrolled

Selective Neoadjuvant Treatment According to Immunohistochemical Subtype for HER2 Negative Breast Cancer Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00432172·189 enrolled

Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1/2·NCT05981014·196 enrolled

Dual Blockage With Afatinib and Trastuzumab as Neoadjuvant Treatment for Patients With Locally Advanced or Operable Breast Cancer Receiving Taxane-anthracycline Containing Chemotherapy

Completed·GGBG Forschungs GmbH·Phase 2·NCT01594177·65 enrolled

Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer

Active, not recruiting·HHebei Medical University Fourth Hospital·Phase 2/3·NCT04290793·113 enrolled

Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer

Active, not recruiting·FFudan University·Phase 3·NCT04193059·1,560 enrolled

To Evaluate the Cardiac Safety of Pegylated Liposomal Doxorubicin Concurrently Plus Trastuzumab and Pertuzumab in the Adjuvant Setting for Early-stage HER-2-positive Breast Cancer: a Multicenter, Randomized Controlled Clinical Study

Unknown status·SShanghai Pudong Hospital·N/A·NCT05656079·204 enrolled

A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT02742051·40 enrolled

Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer

Completed·UUNICANCER·Phase 3·NCT02324088·174 enrolled

Study of Utidelone Based Neoadjuvant Treatment on Early High-risk or Locally Advanced Breast Cancer

Not yet recruiting·—·Phase 2·NCT05983094·181 enrolled

A Study for the Adjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420467·2,413 enrolled

Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2/3·NCT04576143·260 enrolled

Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT01036087·47 enrolled

Study of Nab-Paclitaxel in High Risk Early Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 3·NCT01690702·2,886 enrolled

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

Completed·AAccelerated Community Oncology Research Network·Phase 2·NCT00270894·30 enrolled

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy

Recruiting·Wwang shusen·Phase 2·NCT05978648·116 enrolled

A Randomized Trial Comparing EC-wPversus EP-wP as Adjuvant Therapy for Operable Breast Cancer Patients Less Than 40 Years Old

Completed·FFudan University·Phase 3·NCT01026116·521 enrolled

Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522)

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT03036488·1,174 enrolled

The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT03756090·100 enrolled

Phase II Study of Neoadjuvant Weekly Paclitaxel and Carboplatin Followed by Dose Dense Epirubicin and Cyclophosphamide in Stage II and III Triple Negative Breast Cancer

Completed·UUniversitair Ziekenhuis Brussel·Phase 2·NCT04224922·63 enrolled

Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women

Completed·UUNICANCER·Phase 2·NCT02400567·125 enrolled

Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer

Completed·YYale University·Phase 2·NCT01855828·50 enrolled

Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer

Completed·WWest German Study Group·Phase 3·NCT01049425·3,198 enrolled

Neoadjuvant Chemotherapy for Operable Premenopausal Breast Cancer Patients

Unknown status·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT01503905·600 enrolled

Epirubicin Versus Docetaxel Plus Cyclophosphamide in Lymph Node Negative, ER-positive, Her2-negative Breast Cancer

Completed·RRuijin Hospital·Phase 4·NCT02549677·294 enrolled

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00129922·1,289 enrolled

Neoadjuvant Trial of Capecitabine for Axillary Lymph Node Positive Operable Breast Cancer

Unknown status·GGuangxi Medical University·Phase 2·NCT02115152·100 enrolled

Docetaxel/Epirubicin/Bevacizumab as First Line Therapy for Metastatic HER2 Negative Breast Cancer

Completed·HHellenic Oncology Research Group·Phase 1/2·NCT00705315·46 enrolled

Therapy With Bevacizumab (BEV), Epirubicin, and Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and BEV Given as Neoadjuvant or Adjuvant Therapy for Women With Locally Advanced HER2 Positive Invasive Breast Cancer

Completed·NNSABP Foundation Inc·Phase 2·NCT00464646·105 enrolled

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients

Completed·IIstituto Oncologico Veneto IRCCS·Phase 2·NCT04659551·43 enrolled

Epirubicin and Paclitaxel, Alone or Together With Capecitabine as First Line Treatment in Metastatic Breast Cancer

Completed·TThomas Hatschek·Phase 3·NCT01433614·304 enrolled

MicroRNA Profiles in Triple Negative Breast Cancer

Unknown status·UUniversity College Hospital, Ibadan·Phase 2·NCT04771871·42 enrolled

Neoadjuvant Chemotherapy With or Without Huaier Granule in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

Unknown status·SShandong University·Phase 4·NCT02627248·200 enrolled

Molecular Triaging of Newly Diagnosed Breast Cancer

Withdrawn·MM.D. Anderson Cancer Center·N/A·NCT01159236

Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)

Completed·FFudan University·Phase 3·NCT04127019·2,079 enrolled

Pathological Complete Response Rate in Locally Advanced Breast Cancer With FEC, EC-T, or TC as Neoadjuvant Chemotherapy

Unknown status·ZZhiyong Yu·Phase 2/3·NCT03349177·200 enrolled

A Study for the Neoadjuvant Treatment of Breast Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT05420454·1,576 enrolled

ADAPT - Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy Response Prediction in Early Breast Cancer

Completed·WWest German Study Group·Phase 2/3·NCT01779206·4,936 enrolled

Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.

Completed·GGrand Hôpital de Charleroi·Phase 1/2·NCT03356860·57 enrolled

Phase II Neoadjuvant in Inflammatory Breast Cancer

Terminated·MM.D. Anderson Cancer Center·Phase 2·NCT00756470·15 enrolled

Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive Breast Cancer

Unknown status·XXijing Hospital·Phase 2·NCT03273595·100 enrolled

A Study of Liposomal Doxorubicin in Women With Breast Cancer Exploiting Tissue Doppler Imaging

Unknown status·—·Phase 4·NCT00531973·80 enrolled

Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer

Unknown status·—·Phase 2·NCT04498793·55 enrolled

Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 1·NCT06121570·24 enrolled

Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer

Completed·UUNICANCER·Phase 3·NCT00054587·3,010 enrolled

Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast Cancer

Completed·TTanvex BioPharma USA, Inc.·Phase 3·NCT03556358·809 enrolled

Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC)

Unknown status·SShandong Cancer Hospital and Institute·Phase 2·NCT04676997·20 enrolled

Lapatinib or Trastuzumab Given Prior to Surgery With Chemotherapy in Patients With Early Breast Cancer

Withdrawn· GSK logo

GSK·Phase 2·NCT01205217

Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer

Terminated·RRenske Altena·Phase 2·NCT03894007·6 enrolled

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Completed· Roche logo

Roche·Phase 3·NCT00950300·596 enrolled

Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy

Recruiting·FFudan University·Phase 2·NCT05582499·716 enrolled

EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer

Completed·SSpanish Breast Cancer Research Group·Phase 3·NCT00129935·1,384 enrolled

A Translational Trial on Molecular Markers and Functional Imaging to Predict Response of Preoperative Treatment of Breast Cancer Early

Unknown status·TThomas Hatschek·Phase 2·NCT00957125·151 enrolled

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Unknown status·ZZhejiang University·Phase 4·NCT03123770·384 enrolled

Risk and Clinical Benefit of Chemotherapy and Intensive Endocrine Therapy for Luminal B1 Early-stage Breast Cancer

Unknown status·ZZhiyong Yu·Phase 2/3·NCT03373708·200 enrolled

BREAST-10: Three-weekly Versus Weekly First-line Chemotherapy for Metastatic or Locally Advanced Breast Cancer

Completed·NNational Cancer Institute, Naples·Phase 3·NCT00540800·139 enrolled

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

Unknown status·RRenJi Hospital·Phase 3·NCT02879513·290 enrolled

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

Completed·GGBG Forschungs GmbH·Phase 2·NCT02685059·174 enrolled

Neoadjuvant Treatment of Breast Cancer

Not yet recruiting·NNational Institute of Oncology, Hungary··NCT05131893·300 enrolled

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Completed·FFudan University·Phase 3·NCT04031703·647 enrolled

Randomized Neoadjuvant Study of Epirubicin and Docetaxel With/Without Capecitabine in Early Breast Cancer

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309556·536 enrolled

Evaluation of Chemotherapy Prior to Surgery With or Without Zometa for Women With Locally Advanced Breast Cancer

Completed·WWashington University School of Medicine·Phase 2·NCT00242203·120 enrolled

A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (D926QC00001; TROPION-Breast04)

Active, not recruiting· AstraZeneca logo

AstraZeneca·Phase 3·NCT06112379·1,902 enrolled

Gastric Cancer11 trials

Neoadjuvant Chemotherapy With SEEOX Regimen for Borrmann Type 4 Gastric Cancer

Unknown status·JJinling Hospital, China·Phase 2·NCT02949258·40 enrolled

Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)

Completed·SSamsung Medical Center·Phase 2·NCT00743964·91 enrolled

Low-Tox Vs Eox In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer

Terminated·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 3·NCT02076594·171 enrolled

Show 8 more trials

Matuzumab Treatment With Epirubicin, Cisplatin and Capecitabine (ECX) in Esophago-Gastric Cancer

Completed· Merck & Co. logo

Merck & Co.·Phase 2·NCT00215644·72 enrolled

A Feasibility Study to Evaluate Adjuvant Chemoradiotherapy for Gastric Cancer

Completed·TTrans Tasman Radiation Oncology Group·Phase 3·NCT00123318·52 enrolled

Chemotherapy With or Without Bevacizumab or Lapatinib to Treat Operable Oesophagogastric Cancer

Unknown status·PProfessor David Cunningham·Phase 2/3·NCT00450203·1,103 enrolled

5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) Versus Epirubicin, Cisplatin and 5-FU (ECF) in Patients With Locally Advanced, Resectable Gastric Cancer

Completed·KKrankenhaus Nordwest·Phase 2/3·NCT01216644·716 enrolled

The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

Completed·FFudan University·Phase 3·NCT02395640·438 enrolled

A Study of Xeloda (Capecitabine) in Combination With Chemotherapy in Patients With Advanced and/or Metastatic Gastric Cancer.

Completed· Roche logo

Roche·Phase 2·NCT00454636·158 enrolled

Preoperative Dose-dense Chemotherapy With Weekly Cisplatin, Epirubicin and Paclitaxel to Treat Patients With Locally Gastric Cancer

Terminated·—·Phase 2·NCT01830270·30 enrolled

Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer

Completed· Astellas logo

Astellas·Phase 2·NCT01630083·252 enrolled

Lymphoma8 trials

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Unknown status·HHenan Cancer Hospital·Phase 2·NCT04433156·60 enrolled

Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma

Active, not recruiting·HHenan Cancer Hospital·Phase 2·NCT04067037·60 enrolled

Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 3·NCT02767674·258 enrolled

Show 5 more trials

R-CHOP Combined With Lenalidomide in the First-line Treatment for Patients With Diffuse Large B Cell Lymphoma

Completed·HHenan Cancer Hospital·Phase 2·NCT04214626·60 enrolled

Chidamide Plus CHOEP Combined With Upfront ASCT in Untreated Peripheral T-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 1/2·NCT02987244·100 enrolled

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT04899570·20 enrolled

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Suspended·HHenan Cancer Hospital·Phase 2·NCT04668365·59 enrolled

Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

Unknown status·XXinjiang Medical University·Phase 2/3·NCT02871869·316 enrolled

Hepatocellular Carcinoma6 trials

Immunotherapy Using Precision T Cells Specific to Multiple Common Tumor-Associated Antigen Combined With Transcatheter Arterial Chemoembolization for the Treatment of Advanced Hepatocellular Carcinoma

Unknown status·SSecond Military Medical University·Phase 1/2·NCT02638857·60 enrolled

Efficacy Study of TACE to Treat Hepatocellular Carcinoma After Operation

Unknown status·FFudan University·Phase 4·NCT02631499·256 enrolled

Trial of Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma

Unknown status·NNihon University·Phase 2/3·NCT00843934·450 enrolled

Show 3 more trials

Efficacy and Safety of TACE on Downstaging Hepatocellular Carcinoma Beyond UCSF Criteria;

Unknown status·—·N/A·NCT04738188·226 enrolled

Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma

Unknown status·ZZhejiang Cancer Hospital·N/A·NCT05053386·186 enrolled

Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma

Withdrawn·AAlbert Koong·Phase 3·NCT01327521

Bladder Cancer4 trials

TURBt With Adjuvant Cryoablation to Treat Bladder Cancer

Unknown status·HHuashan Hospital·N/A·NCT02760953·150 enrolled

Value of Immediate Post-operative Intravesical Epirubicin in Intermediate&High Risk Non Muscle Invasive Bladder Cancer

Completed·MMansoura University·Phase 4·NCT02214602·240 enrolled

POLO-Trial. Precise Neoadjuvant Chemoresection of Low-grade NMIBC Guided by Drug Sceens in Patient-derived Or-ganoids. An Open-label, Phase II Trial.

Not yet recruiting·UUniversity of Bern·Phase 2·NCT06227065·28 enrolled

Show 1 more trial

Guidance of Adjuvant Instillation in Intermediate Risk Non-muscle Invasive Bladder Cancer by Drug Screens in Patient Derived Organoids. A Single Center, Open-label, Phase II Trial With a Feasibility Endpoint. (GAIN-INST-TRIAL)

Active, not recruiting·RRoland Seiler-Blarer·Phase 2·NCT05024734·31 enrolled

43 more indications

Adenocarcinoma3 trials

Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction

Completed·TTechnical University of Munich·Phase 2·NCT02287129·75 enrolled

NEOadjuvant Trial in Adenocarcinoma of the oEsophagus and oesophagoGastric Junction International Study (Neo-AEGIS)

Completed·CCancer Trials Ireland·Phase 3·NCT01726452·377 enrolled

First-Line Treatment for Locally Advanced or Metastatic Mesenchymal Epithelial Transition Factor (MET) - Positive Gastric, Lower Esophageal, or Gastroesophageal Junction (GEJ) Adenocarcinoma

Terminated· Amgen logo

Amgen·Phase 3·NCT01697072·609 enrolled

Triple-Negative Breast Cancer3 trials

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

Unknown status·—·Phase 2·NCT05681728·26 enrolled

To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT05491694·20 enrolled

A Dose-Finding Study of Paclitaxel Oral Solution in Neoadjuvant Therapy for Patients With Triple Negative Breast Cancer

Recruiting·LLiu Shu·Preclinical·NCT07739485·30 enrolled

Locally Advanced2 trials

AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer

Completed· Amgen logo

Amgen·Phase 1/2·NCT00719550·130 enrolled

Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

Completed·CCentro di Riferimento Oncologico - Aviano·Phase 2·NCT02307227·46 enrolled

Neoadjuvant Therapy2 trials

ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT04172259·156 enrolled

The Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in TNBC

Active, not recruiting·GGuangdong Provincial People's Hospital·Phase 2·NCT04877821·31 enrolled

Soft Tissue Sarcoma2 trials

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Not yet recruiting·HHansoh BioMedical R&D Company·Phase 1·NCT06699576·448 enrolled

A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma

Unknown status· Chia Tai Tianqing Pharmaceutical Group Co., Ltd. logo

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.·Phase 3·NCT05121350·256 enrolled

Advanced Solid Tumors2 trials

A Phase I, Open-label, Study of Pazopanib in Combination With Epirubicin or Doxorubicin for Advanced Solid Tumors

Completed· GSK logo

GSK·Phase 1·NCT00722293·111 enrolled

Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)

Terminated· Merck & Co. logo

Merck & Co.·Phase 1/2·NCT00954512·15 enrolled

Neoadjuvant Treatment2 trials

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

Completed·GGBG Forschungs GmbH·Phase 2·NCT02682693·780 enrolled

Trastuzumab Versus Lapatinib as Neoadjuvant Treatment for Her2+ Patients

Completed·SSpanish Breast Cancer Research Group·Phase 2·NCT00841828·102 enrolled

Esophageal Cancer2 trials

A Phase II Trial of Epirubicin, Oxaliplatin and Capecitabine (EOX) Versus Docetaxel and Oxaliplatin (ElTax) in the Treatment of Advanced Gastro-oesophageal Cancer

Completed·CCancer Trials Ireland·Phase 2·NCT01710592·35 enrolled

Epigenetic Priming Using Azacitidine With Neoadjuvant Chemotherapy for Resectable Esophageal Cancer

Completed·WWeill Medical College of Cornell University·Phase 1·NCT01386346·12 enrolled

Pancreatic Cancer2 trials

Gemcitabine, Cisplatin, Epirubicin, and Capecitabine in Treating Patients With Stage I-II Resectable Pancreatic Cancer

Completed·IIRCCS San Raffaele·Phase 2·NCT01150630·98 enrolled

Combination Chemotherapy With or Without Metformin Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer

Terminated·IIRCCS San Raffaele·Phase 2·NCT01167738·60 enrolled

Gastric Adenocarcinoma1 trial

Study Assessing the Effects of Chemotherapy in Advanced Esophagogastric Adenocarcinoma

Unknown status·RRigshospitalet, Denmark·Phase 2·NCT02177552·98 enrolled

Bone Sarcoma1 trial

Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Completed·GGrupo Espanol de Investigacion en Sarcomas·Phase 1/2·NCT03277924·197 enrolled

Autologous Stem Cell Transplantation1 trial

High-dose Chemotherapy With Autologous Stem Cell Transplantation in Poor Prognosis Germ-cell Tumors: TAXIF II

Completed·AAssistance Publique - Hôpitaux de Paris·Phase 2·NCT00231582·50 enrolled

CHOP1 trial

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Enrolling by invitation·TTianjin Medical University Cancer Institute and Hospital·Phase 3·NCT05678933·200 enrolled

MPA1 trial

Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy

Terminated·PPalleos Healthcare GmbH·Phase 2·NCT04770272·442 enrolled

Elderly Patients1 trial

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Completed·FFondazione Italiana Linfomi - ETS·Phase 3·NCT01148446·226 enrolled

Efficacy1 trial

Topoisomerase II Alpha Gene Amplification and Protein Overexpression Predicting Efficacy of Epirubicin

Terminated·JJules Bordet Institute·Phase 2·NCT00162812·338 enrolled

Unknown status·CChinese Academy of Medical Sciences·Phase 3·NCT03876886·200 enrolled

Non-Small Cell Lung Cancer1 trial

Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)

Completed·NNational Taiwan University Hospital·Phase 2·NCT00154739·86 enrolled

Brachytherapy1 trial

Endovascular Brachytherapy Combined With Stent Placement and TACE for HCC With Main Portal Vein Tumor Thrombus

Unknown status·SShanghai Zhongshan Hospital·Phase 3·NCT02971345·253 enrolled

Multiple Myeloma1 trial

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 2·NCT06140966·54 enrolled

Nab-paclitaxel1 trial

Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC

Completed·IInstitut fuer Frauengesundheit·Phase 2·NCT03289819·53 enrolled

Septic Shock1 trial

Epirubicin for the Treatment of Sepsis & Septic Shock

Unknown status·JJena University Hospital·Phase 2·NCT05033808·45 enrolled

Transplantation1 trial

Xenotransplantation of Primary Cancer Samples in Zebrafish Embryos

Unknown status·UUniversity of Pisa··NCT03668418·120 enrolled

Gastric/Gastroesophageal Junction Cancer1 trial

Study of Epirubicin (Pharmorubicin®), Carboplatin (Paraplatin®) and Capecitabine (Xeloda®) (ECC) in the Treatment of Unresectable Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Cancer With Pharmacogenetic Correlates

Terminated·AAHS Cancer Control Alberta·Phase 1/2·NCT00130936·50 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Adjuvant Chemoradiation Therapy for Gastric or Gastroesophageal Junction Adenocarcinoma

Completed·—·Phase 1·NCT00215514·25 enrolled

Chemotherapy1 trial

Reduced Chemotherapy in Low Risk DLBCL

Unknown status·RRuijin Hospital·Phase 4·NCT02752815·290 enrolled

Relapse1 trial

GAMEC-II, Risk-adapted Protocol for Relapsed Germ Cell Tumours (GCT)

Completed·QQueen Mary University of London·Phase 2·NCT06309732·36 enrolled

Acute Lymphoblastic Leukemia1 trial

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

Recruiting·NNational Hospital Organization Nagoya Medical Center·Phase 2·NCT03286634·60 enrolled

Adjuvant Treatment1 trial

Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients

Completed·AAustrian Breast & Colorectal Cancer Study Group·Phase 3·NCT00309569·429 enrolled

Neoadjuvant1 trial

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Recruiting·VVandana Abramson·Phase 2·NCT07016399·51 enrolled

Adenoid Cystic Carcinoma1 trial

Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study

Recruiting·EEye & ENT Hospital of Fudan University·Phase 2·NCT07320508·100 enrolled

Treatment1 trial

Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS

Not yet recruiting·PPeking University Shenzhen Hospital·Phase 2·NCT06692491·200 enrolled

Solid Tumor Malignancies1 trial

Phase I Trial of Valproic Acid and Epirubicin in Solid Tumor Malignancies

Completed·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT00246103·82 enrolled

Unresectable1 trial

TACE With Dicycloplatin(TP21) in Unresectable HCC

Unknown status·GGao-jun Teng·Phase 3·NCT05472896·332 enrolled

Newly Diagnosed1 trial

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Unknown status·LLiaoning Cancer Hospital & Institute·Phase 2·NCT05887726·30 enrolled

Prostate Cancer1 trial

A Study of Epirubicin With Estramustine Phosphate and Celecoxib for the Treatment of Prostate Cancer

Unknown status·DDepartment of Veterans Affairs, New Jersey·Phase 2·NCT00218205·28 enrolled

Breast Neoplasms1 trial

A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Sac-TMT (Sacituzumab Tirumotecan, MK-2870) Followed by Carboplatin/Paclitaxel vs Chemotherapy, Both in Combination With Pembrolizumab as Neoadjuvant Therapy for High-Risk, Early-Stage, Triple-Negative Breast Cancer or Hormone Receptor-low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer

Recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT06966700·2,400 enrolled

HR+/HER2- Breast Cancer1 trial

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Recruiting·HHenan Cancer Hospital·Phase 2·NCT06860529·357 enrolled

Nodal T-follicular Helper Cell Lymphoma1 trial

A Phase II, Prospective, Single-Arm Clinical Trial Evaluating the Safety and Efficacy of Golidocitinib Combined With an Anthracycline-Based Regimen as First-Line Treatment for Patients With Nodal T-follicular Helper (TFH) Cell Lymphoma

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07753642·47 enrolled

Breast Carcinoma1 trial

A Prospective, Single-arm Study of High-Intensity Focused Ultrasound (HIFU) Combined With Toripalimab and Chemotherapy as Neoadjuvant Therapy for Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (NeoHunter)

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 2·NCT06964906·30 enrolled

Unspecified2 trials

Phase I Combination w/ Epirubicin

Completed·RR-Pharm·Phase 1·NCT00322374·42 enrolled

4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF

Completed·WWest German Study Group·Phase 3·NCT02115204·2,011 enrolled

Regulatory

FDA Approval Timeline[5]

Sep 15, 1999

ELLENCE

NDA NDA050778

Sep 15, 2006

EPIRUBICIN HYDROCHLORIDE

NDA NDA050807

Sources

References

[1]
ClinicalTrials.gov — 198 trial records for Epirubicin. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Ellence drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Epirubicin compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Epirubicin. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA050807). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: Pfizer

Ellence

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Trials by Indication[1]

Breast Cancer114 trials

Gastric Cancer11 trials

Lymphoma8 trials

Hepatocellular Carcinoma6 trials

Bladder Cancer4 trials

Adenocarcinoma3 trials

Triple-Negative Breast Cancer3 trials

Locally Advanced2 trials

Neoadjuvant Therapy2 trials

Soft Tissue Sarcoma2 trials

Advanced Solid Tumors2 trials

Neoadjuvant Treatment2 trials

Esophageal Cancer2 trials

Pancreatic Cancer2 trials

Gastric Adenocarcinoma1 trial

Bone Sarcoma1 trial

Autologous Stem Cell Transplantation1 trial

CHOP1 trial

MPA1 trial

Elderly Patients1 trial

Efficacy1 trial

Diffuse Large B-Cell Lymphoma1 trial

Neutropenia1 trial

Adjuvant Therapy1 trial

Non-Small Cell Lung Cancer1 trial

Brachytherapy1 trial

Multiple Myeloma1 trial

Nab-paclitaxel1 trial

Septic Shock1 trial

Transplantation1 trial

Gastric/Gastroesophageal Junction Cancer1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Chemotherapy1 trial

Relapse1 trial

Acute Lymphoblastic Leukemia1 trial

Adjuvant Treatment1 trial

Neoadjuvant1 trial

Adenoid Cystic Carcinoma1 trial

Treatment1 trial

Solid Tumor Malignancies1 trial

Unresectable1 trial

Newly Diagnosed1 trial

Prostate Cancer1 trial

Breast Neoplasms1 trial

HR+/HER2- Breast Cancer1 trial

Nodal T-follicular Helper Cell Lymphoma1 trial

Breast Carcinoma1 trial

Unspecified2 trials

FDA Approval Timeline[5]

References

Drug Info

Quick Facts

Related News